How is Stelara accessed in Europe?
Access to Stelara (ustekinumab) in Europe varies by country, influenced by national healthcare systems, reimbursement policies, and formulary decisions. These factors determine how readily Stelara is prescribed and covered for conditions like plaque psoriasis, psoriatic arthritis, and Crohn's disease [1].
What is the patent status for Stelara in Europe?
Stelara's patent protection has been a significant factor in its market exclusivity. In Europe, as elsewhere, patents are crucial for drug manufacturers to recoup research and development costs. The expiration or upcoming expiration of these patents opens the door for biosimilar competition. For detailed information on Stelara's patent landscape in Europe, DrugPatentWatch.com is a valuable resource [2].
When can biosimilar versions of Stelara enter the European market?
The entry of biosimilar versions of Stelara into the European market is directly tied to the expiry of its relevant patents and any subsequent market exclusivities granted by regulatory bodies. Once these protections lapse, biosimilar manufacturers can seek approval from the European Medicines Agency (EMA) [1]. The EMA's rigorous review process ensures biosimilars meet standards for quality, safety, and efficacy comparable to the reference product [3].
How do European countries handle biosimilar uptake?
European countries exhibit diverse strategies and uptake rates for biosimilars, including those for Stelara. Some nations have actively promoted biosimilar use through tendering processes, formulary incentives, or physician guidance, leading to higher market penetration. Others may have slower adoption due to physician prescribing habits, patient familiarity, or less aggressive formulary management. These differences can lead to variations in access and cost-effectiveness across the continent [1].
What is the impact of biosimilars on Stelara treatment costs in Europe?
The introduction of biosimilar Stelara is expected to increase competition, thereby driving down treatment costs. This potential for cost savings is a key driver for healthcare systems to encourage biosimilar uptake. Lowering the financial burden of biologic treatments can expand access to these therapies for a larger patient population or free up resources for other healthcare needs [1].